Care Home Communication

This document outlines key areas to share with your loved one’s care home staff. Please note, the information below is based on personal struggles/challenges with care homes experienced by my […]

uniQure Provides Regulatory Update

Dear Huntington’s Disease Community, We are writing to share an update following our recent Type A meeting with the U.S. Food and Drug Administration (FDA.) On March 2, 2026, uniQure […]

Novartis Announces INVEST-HD

Novartis development of Votoplam in HD: INVEST-HD Phase 3 trial information now available February 3rd 2026 Dear Huntington’s disease Community, We are delighted to share an update on the development […]

An Update on SKY-0515

Dear friends in the Huntington’s disease community, We’d like to share an update on ongoing research into SKY-0515, an investigational medicine being studied for Huntington’s disease (HD). A scientific press […]

uniQure Announces Meeting with FDA

January 9, 2026 7:05 AM EST uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading […]

An Update from LoQus23

LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic dystrophy type […]